Published online before print November 24, 2008, doi: 10.1161/CIRCULATIONAHA.108.772582
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2008;118:2498-2505.)
© 2008 American Heart Association, Inc.
Arrhythmia/Electrophysiology |
Catheter Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation
The A4 Study
From the Hôpital Cardiologique du Haut-Lévêque, Bordeaux-Pessac, France (P.J., M.H., F.S., P.B., J.C., M.H.); Hôpital Larriboisière, Paris, France (B.C., F.E.); Montreal Heart Institute, Montreal, Canada (L.M., P.K.); Richard M. Ross Heart Hospital, Columbus, Ohio (E.D.); Department of Cardiology, St. Vincent’s Hospital, Sydney, Australia (R.S.); University Hospital, London, Canada (G.K.); and University of Western Australia, Crawley, Western Australia (R.W.).
Correspondence to Dr Pierre Jais, Hôpital Cardiologique du Haut-Lévêque, Avenue de Magellan, 33604 Bordeaux-Pessac, France. E-mail pierre.jais{at}chu-bordeaux.fr
Received February 20, 2008; accepted September 19, 2008.
Background— The mainstay of treatment for atrial fibrillation (AF) remains pharmacological; however, catheter ablation has increasingly been used over the last decade. The relative merits of each strategy have not been extensively studied.
Methods and Results— We conducted a randomized multicenter comparison of these 2 treatment strategies in patients with paroxysmal AF resistant to at least 1 antiarrhythmic drug. The primary end point was absence of recurrent AF between months 3 and 12, absence of recurrent AF after up to 3 ablation procedures, or changes in antiarrhythmic drugs during the first 3 months. Ablation consisted of pulmonary vein isolation in all cases, whereas additional extrapulmonary vein lesions were at the discretion of the physician. Crossover was permitted at 3 months in case of failure. Echocardiographic data, symptom score, exercise capacity, quality of life, and AF burden were evaluated at 3, 6, and 12 months by the supervising committee. Of 149 eligible patients, 112 (18 women [16%]; age, 51.1±11.1 years) were enrolled and randomized to ablation (n=53) or "new" antiarrhythmic drugs alone or in combination (n=59). Crossover from the antiarrhythmic drugs and ablation groups occurred in 37 (63%) and 5 patients (9%), respectively (P=0.0001). At the 1-year follow-up, 13 of 55 patients (23%) and 46 of 52 patients (89%) had no recurrence of AF in the antiarrhythmic drug and ablation groups, respectively (P<0.0001). Symptom score, exercise capacity, and quality of life were significantly higher in the ablation group.
Conclusion— This randomized multicenter study demonstrates the superiority of catheter ablation over antiarrhythmic drugs in patients with AF with regard to maintenance of sinus rhythm and improvement in symptoms, exercise capacity, and quality of life.
CLINICAL PERSPECTIVE
Related Article:
-
Clinical Summaries
Circulation 2008 118: 2485-2487.[Extract] [Full Text]
This article has been cited by other articles:
 |
|
 |
|
  D. W. Davies and M. D O'Neill What now for atrial fibrillation ablation? Heart, November 1, 2009; 95(21): 1723 - 1724. [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Burkhardt and A. Natale New Technologies in Atrial Fibrillation Ablation Circulation, October 13, 2009; 120(15): 1533 - 1541. [Full Text] [PDF]
|
|
|
|
|
|
D. G. Wyse Cardioversion of Atrial Fibrillation for Maintenance of Sinus Rhythm: A Road to Nowhere Circulation, October 6, 2009; 120(14): 1444 - 1452. [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Lindsay Should catheter ablation be the first line of treatment for atrial fibrillation? Cleveland Clinic Journal of Medicine, September 1, 2009; 76(9): 503 - 506. [Full Text] [PDF]
|
|
|
|
|
|
P. CHOWDHURY, W. R. LEWIS, R. A. SCHWEIKERT, and J. E. CUMMINGS Ablation of atrial fibrillation: What can we tell our patients? Cleveland Clinic Journal of Medicine, September 1, 2009; 76(9): 543 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Terasawa, E. M. Balk, M. Chung, A. C. Garlitski, A. A. Alsheikh-Ali, J. Lau, and S. Ip Systematic Review: Comparative Effectiveness of Radiofrequency Catheter Ablation for Atrial Fibrillation Ann Intern Med, August 4, 2009; 151(3): 191 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Reynolds, P. Zimetbaum, M. E. Josephson, E. Ellis, T. Danilov, and D. J. Cohen Cost-Effectiveness of Radiofrequency Catheter Ablation Compared With Antiarrhythmic Drug Therapy for Paroxysmal Atrial Fibrillation Circ Arrhythm Electrophysiol, August 1, 2009; 2(4): 362 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Halimi, L. Van Erven, and on behalf of the EHRA Scientific Initiatives Commi Validation of success following atrial fibrillation ablation: a European survey Europace, August 1, 2009; 11(8): 1002 - 1003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Aistrup, R. Villuendas, J. Ng, A. Gilchrist, T. W. Lynch, D. Gordon, I. Cokic, S. Mottl, R. Zhou, D. A. Dean, et al. Targeted G-protein inhibition as a novel approach to decrease vagal atrial fibrillation by selective parasympathetic attenuation Cardiovasc Res, August 1, 2009; 83(3): 481 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. J. Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, et al. Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation' Europace, July 1, 2009; 11(7): 860 - 885. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Crandall, D. J. Bradley, D. L. Packer, and S. J. Asirvatham Contemporary Management of Atrial Fibrillation: Update on Anticoagulation and Invasive Management Strategies Mayo Clin. Proc., July 1, 2009; 84(7): 643 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. John Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF' Eur. Heart J., June 17, 2009; (2009) ehp235v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. Forleo and C. Tondo Atrial fibrillation: cure or treat? Therapeutic Advances in Cardiovascular Disease, June 1, 2009; 3(3): 187 - 196. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Belhassen A 1 per 1,000 mortality rate after catheter ablation of atrial fibrillation an acceptable risk? J. Am. Coll. Cardiol., May 12, 2009; 53(19): 1804 - 1806. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Callans Apples and Oranges: Comparing Antiarrhythmic Drugs and Catheter Ablation for Treatment of Atrial Fibrillation Circulation, December 9, 2008; 118(24): 2488 - 2490. [Full Text] [PDF]
|
|